AzTrials
AzTrials

Smoking CessationPhase 4NCT06474299

The Avenues Study: Dual Use Cessation

A Phase 4 study testing Varenicline, Nicotine patch and Dual Focused Cessation Counseling in people with Smoking Cessation and Electronic Cigarette Use, run by University of Wisconsin, Madison at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Smoking Cessation, Electronic Cigarette Use
What is being tested?
Varenicline, Nicotine patch and Dual Focused Cessation Counseling
Could I receive a placebo?
No, everyone receives an active treatment
How many people
500 participants
Where
1 siteUnited States
Study dates
24 Sep 2024to Jul 2028
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Able to read and communicate in English
  • Willing to set a quit date to quit smoking cigarettes in the next 30 days
  • Willing and medically able to use varenicline and nicotine patches
  • Smoking ≥ 5 cigarettes per day for the past 6 months
  • Vaping weekly for at least 6 months
  • Willing to stop using nicotine replacement or varenicline
Show all 11Show fewer
  • Willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation
  • Saliva cotinine >30 ng/ml
  • US resident
  • Own a Smartphone to use and download an app to record data
  • have a working email so that they can receive links for video visits

Who cannot join

  • Currently in treatment for psychosis or bipolar disorder
  • If they are currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)
  • Currently pregnant or breastfeeding. If a participant becomes pregnant while in the study, they will be allowed to continue in the study but will no longer receive study medications. They will also be asked to return any unused study medications.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • University of Wisconsin-Madison School of Medicine and Public Health

    Madison, Wisconsin, 53792

    Mark Zehner, 608-262-7568, mark.zehner@wisc.edu

    Megan Piper, PhD

    Recruiting

Other trials in United States

About this study

Official title: Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape

The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.

Read the detailed description

To be efficient and maximize translation potential, the investigators will use the efficient Multiphase Optimization Strategy (MOST) to identify an optimal intervention to help people who use both cigarettes and ENDS quit smoking cigarettes. As such, in this randomized 2x2x2 factorial screening trial, the investigators will examine three intervention components:

  1. Pharmacotherapy (varenicline vs. nicotine patch)
  2. Counseling Intensity (4 vs. 1 session)
  3. Counseling Approach (Dual Focused vs. Smoking Focused).

The Dual Focused counseling approach will encourage participants to quit their ENDS use as part of their smoking cessation attempt. The Smoking Focused counseling approach will encourage participants to quit smoking but not vaping and to use their ENDS strategically to deal with urges in service of harm reduction. There is theoretical and empirical support for these pharmacologic and counseling approaches and intensities.

Participants (N=500) will be dual users of cigarettes (>4 cigs/day for the last 6 months) and ENDS (vape weekly for at least 6 months) who are motivated to quit smoking and willing try to quit vaping, if asked to do so. Participants will be recruited, assessed, and treated remotely. They will be randomized to receive either varenicline or nicotine patches for 12 weeks, to receive either one or four 15-20-minute counseling sessions, and to receive counseling that is either dual focused or smoking focused. Dual Focused Cessation will focus on quitting both smoking and vaping on the target quit date (TQD). Pre-TQD, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places or at specific times of day). Post-TQD, participants will focus on building smoking and vaping cessation skills (e.g., coping with cravings to smoke or vape, avoiding smoking and vaping cues). Smoking Focused Cessation will focus on quitting smoking on the TQD and using ENDS as a behavioral substitute (i.e., using ENDS as a cigarette substitute). Pre-TQD, participants will be instructed to change smoking patterns (e.g., vaping rather than smoking in specific places or at specific times of day, vaping first in the morning rather than smoking) and practice smoking cessation coping strategies (e.g., substituting ENDS for cigarettes, avoiding smoking cues). Participants will be advised to quit smoking on the TQD and not worry about quitting vaping at this point. Participants will complete daily measures of smoking, vaping, and potential change mechanisms (e.g., craving, smoking reward, self-efficacy) via ecological momentary assessment (EMA) for 2 weeks pre-TQD and 2 weeks post-TQD. Follow-up will occur for 12 months post-TQD.

Primary Objective: Determine which pharmacologic and counseling approaches are especially effective, alone or in combination, in helping dual users quit smoking.

Secondary Objectives:

  • Examine the effects of the treatments on variables that may mediate treatment effects on smoking cessation.
  • Examine
  1. changes in vaping intensity and vaping cessation
  2. moderators of treatment effects (e.g., cigarette dependence, race, menthol use, ENDS characteristics), and
  3. whether continued vaping is related to cigarette lapse and relapse amongst those who have quit smoking.
Being tested
Varenicline, Nicotine patch, Dual Focused Cessation Counseling, Smoking Focused Cessation Counseling, Counseling Intensity: 1 Session
Keywords
ENDS, Cessation
Medical subject headings
Smoking Cessation, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VareniclineDrug

    0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily

  • Nicotine patchDrug

    Following package inserts starting on the TQD, participants who smoke >10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.

  • Dual Focused Cessation CounselingBehavioural

    Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).

  • Smoking Focused Cessation CounselingBehavioural

    Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).

  • Counseling Intensity: 1 SessionOther

    Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).

  • Counseling Intensity: 4 SessionsOther

    Participants assigned to intensive counseling will have four, 15-20-minute sessions.

Study groups in NCT06474299
Study groupRoleWhat they receive
Varenicline, Dual Focused, 1 sessionActive comparatorNot described
Receives: Drug: Varenicline; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 1 Session
Varenicline, Dual Focused, 4 sessionsActive comparatorNot described
Receives: Drug: Varenicline; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions
Varenicline, Smoking Focused, 1 sessionActive comparatorNot described
Receives: Drug: Varenicline; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 1 Session
Varenicline, Smoking Focused, 4 sessionsActive comparatorNot described
Receives: Drug: Varenicline; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions
Nicotine Patches, Dual Focused, 1 sessionActive comparatorNot described
Receives: Drug: Nicotine patch; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 1 Session
Nicotine Patches, Dual Focused, 4 sessionsActive comparatorNot described
Receives: Drug: Nicotine patch; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions
Nicotine Patches, Smoking Focused, 1 sessionActive comparatorNot described
Receives: Drug: Nicotine patch; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 1 Session
Nicotine Patches, Smoking Focused, 4 sessionsActive comparatorNot described
Receives: Drug: Nicotine patch; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes

    52-week biochemically confirmed (anabasine<2 ng/ml) 7-day point-prevalence abstinence from cigarettes

    Measured: up to 52 weeks

Secondary outcomes (2)
  1. 26-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes

    26-week biochemically confirmed (anabasine<2 ng/ml) 7-day point-prevalence abstinence from cigarettes

    Measured: up to 26 weeks

  2. 7-day point-prevalence abstinence from smoking and vaping at Weeks 26 and 52 post-TQD

    Biochemically confirmed with saliva cotinine <30 ng/mL

    Measured: up to 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2024
  2. Study start24 Sep 2024
  3. Primary completionJul 2028 (estimated)
  4. Study completionJul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
2x2x2 factorial screening trial
Masking
None (open label)
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06474299
Sponsor's protocol ID
2024-0019
Other IDs
R01CA290895, A534253, SMPH/MEDICINE/GEN INT MD, Protocol Version 9/4/2026
Status last verified
Oct 2026
First submitted
19 Jun 2024
Last updated
7 Oct 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Varenicline, Nicotine patch and Dual Focused Cessation Counseling in people with Smoking Cessation and Electronic Cigarette Use, run by University of Wisconsin, Madison at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mark Zehner (608-262-7568, mark.zehner@wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes (time frame: up to 52 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in